Retatrutide, by Soma Corp., is attracting considerable attention as a innovative treatment for metabolic regulation. This dual-action compound merges the properties of a GLP-1 receptor stimulant and a GIP receptor agonist , intended to effectively promote reduced body fat but also address related metabolic factors. Preliminary clinical data have sh